TG Therapeutics, Inc. (TGTX) Short Interest Update
TG Therapeutics, Inc. (NASDAQ:TGTX) was the recipient of a large drop in short interest in the month of November. As of November 30th, there was short interest totalling 15,880,967 shares, a drop of 11.2% from the November 15th total of 17,893,222 shares. Currently, 28.2% of the shares of the stock are sold short. Based on an average trading volume of 1,400,762 shares, the days-to-cover ratio is presently 11.3 days.
Shares of TG Therapeutics (TGTX) opened at $8.20 on Thursday. TG Therapeutics has a one year low of $4.10 and a one year high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last announced its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The business had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. analysts anticipate that TG Therapeutics will post -1.86 earnings per share for the current year.
TGTX has been the topic of a number of research analyst reports. B. Riley initiated coverage on shares of TG Therapeutics in a research note on Friday, December 1st. They issued a “buy” rating and a $21.50 price target on the stock. BidaskClub raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 24th. SunTrust Banks reissued a “buy” rating and issued a $28.00 price target on shares of TG Therapeutics in a research note on Tuesday, October 3rd. HC Wainwright reissued a “buy” rating and issued a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $25.50.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.